While these disorders have long been considered untreatable, recent advances in molecular biology have led to the first FDA-approved gene therapy for a retinal dystrophy, voretigene neparvovec-rzyl (LUXTURNA) for RPE65-associated Leber congenital amaurosis (LCA). This evidence concerns the gene RPE65 and Leber congenital amaurosis.